论文部分内容阅读
目的:探讨神经钙粘素(N-Cadherin)在多发性骨髓瘤(multiple myeloma,MM)患者骨髓瘤细胞中的表达及临床意义。方法:应用流式细胞术检测64例MM患者CD38+/CD138+细胞中N-Cadherin表达水平,分析其与临床特征及预后的相关性。结果:在64例MM患者中有17例(26.56%)骨髓瘤细胞神经钙粘素高表达(>20%),47例(73.44%)神经钙粘素低表达(≤20%)。神经钙粘素高表达与低表达患者在疾病的分期、分型、已知的多发性骨髓瘤预后因素、骨髓瘤细胞免疫分型、骨质破坏程度方面的差异均无统计学意义(P>0.05)。神经钙粘素高表达组1q21扩增阳性率明显增高(P<0.05),而两组间RB1缺失、D13S319缺失及IGH重排检出率均无统计学差异。神经钙粘素高表达和低表达患者中位总体生存时间(OS)分别为26.7月和55.5月,两组间差异有统计学意义(P<0.05)。结论:神经钙粘素高表达可能是多发性骨髓瘤预后不良的指标之一,这可能与1q21扩增有关。
Objective: To investigate the expression and clinical significance of N-Cadherin in myeloma cells from multiple myeloma (MM) patients. Methods: The expression of N-Cadherin in CD38 + / CD138 + cells of 64 MM patients was detected by flow cytometry, and its correlation with clinical features and prognosis was analyzed. RESULTS: Among 64 MM patients, 17 (26.56%) had high expression of cadherin (> 20%) and 47 (73.44%) showed low expression of cadherin (≤20%). There was no significant difference in the stage of staging, typing, prognosis of known multiple myeloma, immunophenotyping of myeloma cells, and the degree of bone destruction among patients with high expression and low expression of cadherin (P> 0.05). The positive rate of 1q21 amplification was significantly higher in high cadherin expression group (P <0.05), while there was no significant difference between the two groups in RB1 deletion, D13S319 deletion and IGH rearrangement detection rate. The overall median survival time (OS) of patients with high expression and low expression of cadherin were 26.7 months and 55.5 months, respectively, with significant difference between the two groups (P <0.05). Conclusion: The high expression of cadherin may be one of the indicators of poor prognosis of multiple myeloma, which may be related to 1q21 amplification.